Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates

Autor: Ana Paula Silva de Lemos, Stefania Bambini, Mariagrazia Pizza, Eva Hong, Sonia Budroni, Ray Borrow, Gabriella De Angelis, Ulrich Vogel, Maria Cecília Gorla, Philip Boucher, Rino Rappuoli, Maria Giuliani, Marzia Monica Giuliani, Sara Tomei, Maurizio Comanducci, Muhamed-Kheir Taha, Jay Lucidarme, Brunella Brunelli, Monica Moschioni, Heike Claus, Alessia Biolchi

Publikováno v: Vaccine
Vaccine, Elsevier, 2020, 38 (47), pp.7542-7550. ⟨10.1016/j.vaccine.2020.09.050⟩
Vaccine, 2020, 38 (47), pp.7542-7550. ⟨10.1016/j.vaccine.2020.09.050⟩

International audience; Background: The multicomponent meningococcal serogroup B vaccine (4CMenB) is currently indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). However, gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2879694d4772ef801fb97a0d09b57017
https://hal-pasteur.archives-ouvertes.fr/pasteur-03265134